 John Kincaid
Concepts (227)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Electrodiagnosis | 4 | 2020 | 13 | 1.880 |
Why?
| | Neural Conduction | 7 | 2021 | 34 | 1.570 |
Why?
| | Neurology | 3 | 2023 | 33 | 1.250 |
Why?
| | Electromyography | 4 | 2022 | 127 | 1.230 |
Why?
| | Ultrasonography | 2 | 2020 | 423 | 1.150 |
Why?
| | Societies, Medical | 6 | 2023 | 202 | 1.080 |
Why?
| | Neurophysiology | 5 | 2024 | 9 | 0.880 |
Why?
| | Polyneuropathies | 3 | 2017 | 6 | 0.850 |
Why?
| | Neuromuscular Diseases | 2 | 2022 | 31 | 0.840 |
Why?
| | Peripheral Nervous System Diseases | 2 | 2019 | 58 | 0.750 |
Why?
| | Axons | 1 | 2021 | 48 | 0.720 |
Why?
| | Dictionaries as Topic | 1 | 2020 | 1 | 0.670 |
Why?
| | Terminology as Topic | 1 | 2020 | 71 | 0.630 |
Why?
| | Amyloid Neuropathies, Familial | 4 | 2020 | 5 | 0.520 |
Why?
| | Oligonucleotides | 3 | 2020 | 76 | 0.460 |
Why?
| | Disease Progression | 3 | 2020 | 872 | 0.430 |
Why?
| | Hypoglycemic Agents | 3 | 2017 | 217 | 0.400 |
Why?
| | Health Care Costs | 1 | 2014 | 176 | 0.390 |
Why?
| | Nervous System Diseases | 1 | 2014 | 94 | 0.390 |
Why?
| | Diabetes Mellitus | 2 | 2024 | 317 | 0.380 |
Why?
| | Amyloidosis, Familial | 1 | 2011 | 2 | 0.360 |
Why?
| | Neurologic Examination | 1 | 2011 | 73 | 0.350 |
Why?
| | Humans | 37 | 2024 | 52469 | 0.350 |
Why?
| | Peripheral Nerves | 2 | 2007 | 44 | 0.340 |
Why?
| | Oligonucleotides, Antisense | 2 | 2020 | 29 | 0.340 |
Why?
| | Amyloid Neuropathies | 2 | 2007 | 2 | 0.330 |
Why?
| | Diabetic Neuropathies | 2 | 2007 | 56 | 0.330 |
Why?
| | Skin Neoplasms | 2 | 2024 | 500 | 0.290 |
Why?
| | Motor Neurons | 1 | 2007 | 37 | 0.280 |
Why?
| | Neurons, Afferent | 1 | 2007 | 22 | 0.280 |
Why?
| | Molecular Biology | 1 | 2007 | 27 | 0.270 |
Why?
| | Myotonic Dystrophy | 2 | 2022 | 13 | 0.270 |
Why?
| | Larynx | 2 | 2020 | 30 | 0.270 |
Why?
| | Cryptochromes | 2 | 2017 | 5 | 0.270 |
Why?
| | Carbazoles | 2 | 2017 | 18 | 0.260 |
Why?
| | Electrocardiography | 3 | 2016 | 279 | 0.250 |
Why?
| | Protein Kinase Inhibitors | 2 | 2024 | 226 | 0.230 |
Why?
| | Muscle, Skeletal | 3 | 2020 | 809 | 0.230 |
Why?
| | Accessory Nerve Diseases | 1 | 2003 | 1 | 0.210 |
Why?
| | Neurofibromatosis 1 | 1 | 2024 | 33 | 0.210 |
Why?
| | Neoplasms, Germ Cell and Embryonal | 1 | 2024 | 20 | 0.210 |
Why?
| | Tongue Neoplasms | 1 | 2003 | 12 | 0.210 |
Why?
| | Testicular Neoplasms | 1 | 2024 | 46 | 0.210 |
Why?
| | Neuralgia | 1 | 2024 | 42 | 0.210 |
Why?
| | United States | 7 | 2024 | 5225 | 0.200 |
Why?
| | Carcinoma | 1 | 2003 | 137 | 0.190 |
Why?
| | Demyelinating Diseases | 1 | 2002 | 7 | 0.190 |
Why?
| | Guillain-Barre Syndrome | 1 | 2002 | 12 | 0.190 |
Why?
| | Blood Component Removal | 1 | 2002 | 17 | 0.180 |
Why?
| | Neuromuscular Junction | 1 | 2021 | 9 | 0.180 |
Why?
| | Virus Diseases | 1 | 2022 | 46 | 0.180 |
Why?
| | Myelin Sheath | 1 | 2021 | 26 | 0.180 |
Why?
| | Practice Guidelines as Topic | 2 | 2020 | 496 | 0.180 |
Why?
| | Hypersensitivity | 1 | 2022 | 81 | 0.180 |
Why?
| | Laryngoplasty | 1 | 2020 | 8 | 0.170 |
Why?
| | Laryngectomy | 1 | 2020 | 27 | 0.170 |
Why?
| | Insulin | 1 | 2003 | 484 | 0.170 |
Why?
| | Prealbumin | 3 | 2007 | 22 | 0.170 |
Why?
| | Carcinoma, Squamous Cell | 1 | 2023 | 330 | 0.170 |
Why?
| | Tissue Scaffolds | 1 | 2020 | 40 | 0.170 |
Why?
| | Diabetes Mellitus, Type 1 | 1 | 2003 | 221 | 0.170 |
Why?
| | Muscle Weakness | 1 | 2020 | 45 | 0.160 |
Why?
| | Health Personnel | 1 | 2023 | 252 | 0.160 |
Why?
| | Tibial Nerve | 2 | 2011 | 6 | 0.160 |
Why?
| | Tissue Engineering | 1 | 2020 | 74 | 0.160 |
Why?
| | Male | 15 | 2024 | 26794 | 0.160 |
Why?
| | Lower Extremity | 1 | 2020 | 99 | 0.160 |
Why?
| | Action Potentials | 2 | 2011 | 120 | 0.160 |
Why?
| | Middle Aged | 11 | 2024 | 13084 | 0.160 |
Why?
| | Upper Extremity | 1 | 2019 | 45 | 0.150 |
Why?
| | Quality of Life | 2 | 2024 | 881 | 0.140 |
Why?
| | Asthma | 1 | 2022 | 316 | 0.140 |
Why?
| | Amides | 1 | 2017 | 37 | 0.140 |
Why?
| | Urea | 1 | 2017 | 82 | 0.140 |
Why?
| | Parainfluenza Virus 3, Human | 1 | 2017 | 5 | 0.140 |
Why?
| | Respirovirus Infections | 1 | 2017 | 6 | 0.140 |
Why?
| | Physicians | 2 | 2023 | 240 | 0.140 |
Why?
| | Diagnostic Techniques, Neurological | 1 | 2017 | 5 | 0.130 |
Why?
| | Drug Discovery | 1 | 2017 | 93 | 0.130 |
Why?
| | Sympathetic Nervous System | 1 | 2016 | 17 | 0.130 |
Why?
| | Immunocompromised Host | 1 | 2017 | 123 | 0.130 |
Why?
| | Tachycardia, Ventricular | 1 | 2016 | 46 | 0.120 |
Why?
| | Orphan Drug Production | 1 | 2015 | 1 | 0.120 |
Why?
| | Neuromuscular Junction Diseases | 1 | 2015 | 1 | 0.120 |
Why?
| | 4-Aminopyridine | 1 | 2015 | 3 | 0.120 |
Why?
| | Potassium Channel Blockers | 1 | 2015 | 16 | 0.120 |
Why?
| | Adult | 8 | 2024 | 14151 | 0.120 |
Why?
| | High-Throughput Nucleotide Sequencing | 1 | 2017 | 179 | 0.120 |
Why?
| | Antineoplastic Agents | 1 | 2024 | 1217 | 0.120 |
Why?
| | TRPV Cation Channels | 1 | 2015 | 8 | 0.120 |
Why?
| | Sulfonamides | 1 | 2015 | 133 | 0.110 |
Why?
| | Piperazines | 1 | 2015 | 125 | 0.110 |
Why?
| | Mitogen-Activated Protein Kinase Kinases | 2 | 2024 | 34 | 0.110 |
Why?
| | Severity of Illness Index | 1 | 2017 | 1038 | 0.100 |
Why?
| | Female | 11 | 2024 | 28192 | 0.100 |
Why?
| | Skin | 1 | 2016 | 420 | 0.100 |
Why?
| | Vocal Cord Paralysis | 1 | 2012 | 23 | 0.100 |
Why?
| | Evoked Potentials, Motor | 1 | 2011 | 9 | 0.090 |
Why?
| | Heart Conduction System | 1 | 2011 | 25 | 0.090 |
Why?
| | Hypertrophy, Left Ventricular | 1 | 2011 | 43 | 0.090 |
Why?
| | Structure-Activity Relationship | 3 | 2017 | 405 | 0.090 |
Why?
| | Magnetic Resonance Imaging, Cine | 1 | 2011 | 63 | 0.080 |
Why?
| | Sural Nerve | 2 | 2007 | 7 | 0.080 |
Why?
| | Synkinesis | 1 | 2009 | 2 | 0.080 |
Why?
| | Phenol | 1 | 2009 | 7 | 0.080 |
Why?
| | Recurrent Laryngeal Nerve Injuries | 1 | 2009 | 6 | 0.080 |
Why?
| | Sclerosing Solutions | 1 | 2009 | 16 | 0.080 |
Why?
| | Tubulin Modulators | 1 | 2009 | 28 | 0.080 |
Why?
| | Vincristine | 1 | 2009 | 88 | 0.080 |
Why?
| | Predictive Value of Tests | 2 | 2012 | 944 | 0.080 |
Why?
| | West Nile Fever | 1 | 2008 | 4 | 0.080 |
Why?
| | Heart Ventricles | 1 | 2011 | 267 | 0.080 |
Why?
| | Paralysis | 1 | 2008 | 8 | 0.070 |
Why?
| | Aged | 4 | 2020 | 10193 | 0.070 |
Why?
| | Treatment Outcome | 4 | 2024 | 5471 | 0.070 |
Why?
| | Animals | 6 | 2023 | 13455 | 0.070 |
Why?
| | Follow-Up Studies | 2 | 2011 | 2288 | 0.070 |
Why?
| | Spinal Cord Diseases | 1 | 2008 | 39 | 0.070 |
Why?
| | Mice | 4 | 2023 | 5936 | 0.070 |
Why?
| | Vibration | 1 | 2007 | 7 | 0.070 |
Why?
| | Peroneal Nerve | 1 | 2007 | 6 | 0.070 |
Why?
| | Echocardiography | 1 | 2011 | 414 | 0.070 |
Why?
| | Death, Sudden, Cardiac | 1 | 2008 | 60 | 0.070 |
Why?
| | Sensory Receptor Cells | 1 | 2007 | 11 | 0.070 |
Why?
| | Gelsolin | 1 | 2007 | 1 | 0.070 |
Why?
| | Apolipoprotein A-I | 1 | 2007 | 6 | 0.070 |
Why?
| | Arrhythmias, Cardiac | 1 | 2008 | 98 | 0.070 |
Why?
| | Heart Rate | 2 | 2020 | 317 | 0.070 |
Why?
| | Reaction Time | 1 | 2007 | 208 | 0.070 |
Why?
| | Amyloid | 2 | 2003 | 36 | 0.060 |
Why?
| | Child | 4 | 2022 | 7188 | 0.060 |
Why?
| | Decompression, Surgical | 1 | 2006 | 50 | 0.060 |
Why?
| | Molecular Structure | 2 | 2017 | 315 | 0.060 |
Why?
| | Diabetes Mellitus, Experimental | 2 | 2017 | 137 | 0.060 |
Why?
| | Sensitivity and Specificity | 1 | 2007 | 883 | 0.060 |
Why?
| | Neurofibroma | 1 | 2024 | 16 | 0.050 |
Why?
| | Administration, Topical | 1 | 2024 | 60 | 0.050 |
Why?
| | Genetic Variation | 2 | 2003 | 229 | 0.050 |
Why?
| | Societies | 1 | 2024 | 8 | 0.050 |
Why?
| | Chemoprevention | 1 | 2023 | 19 | 0.050 |
Why?
| | Clinical Trials as Topic | 1 | 2006 | 471 | 0.050 |
Why?
| | Sciatic Nerve | 1 | 2003 | 19 | 0.050 |
Why?
| | Dose-Response Relationship, Drug | 2 | 2017 | 1372 | 0.050 |
Why?
| | Survivors | 1 | 2024 | 118 | 0.050 |
Why?
| | Obesity | 2 | 2024 | 1164 | 0.050 |
Why?
| | Certification | 1 | 2023 | 51 | 0.050 |
Why?
| | Education, Medical, Continuing | 1 | 2023 | 72 | 0.050 |
Why?
| | Multiple Myeloma | 1 | 2017 | 3050 | 0.050 |
Why?
| | Cross-Sectional Studies | 1 | 2007 | 1680 | 0.050 |
Why?
| | Adolescent | 2 | 2024 | 6708 | 0.050 |
Why?
| | Respiratory Sounds | 1 | 2022 | 50 | 0.050 |
Why?
| | Genetic Testing | 1 | 2022 | 130 | 0.050 |
Why?
| | Mutation | 1 | 2007 | 1339 | 0.050 |
Why?
| | Laryngeal Cartilages | 1 | 2020 | 1 | 0.040 |
Why?
| | Motor Endplate | 1 | 2020 | 3 | 0.040 |
Why?
| | Swine, Miniature | 1 | 2020 | 17 | 0.040 |
Why?
| | Recurrent Laryngeal Nerve | 1 | 2020 | 12 | 0.040 |
Why?
| | Phonation | 1 | 2020 | 13 | 0.040 |
Why?
| | Myoblasts | 1 | 2020 | 19 | 0.040 |
Why?
| | Primary Cell Culture | 1 | 2020 | 62 | 0.040 |
Why?
| | Reflex | 1 | 2020 | 29 | 0.040 |
Why?
| | Pain | 1 | 2003 | 359 | 0.040 |
Why?
| | Symptom Assessment | 1 | 2020 | 32 | 0.040 |
Why?
| | Deglutition | 1 | 2020 | 44 | 0.040 |
Why?
| | Cell Proliferation | 1 | 2023 | 1024 | 0.040 |
Why?
| | Swine | 1 | 2020 | 427 | 0.040 |
Why?
| | Adipose Tissue | 1 | 2020 | 204 | 0.040 |
Why?
| | Double-Blind Method | 1 | 2020 | 718 | 0.040 |
Why?
| | Pilot Projects | 1 | 2020 | 719 | 0.040 |
Why?
| | Emergency Service, Hospital | 1 | 2022 | 524 | 0.040 |
Why?
| | Cell Differentiation | 1 | 2020 | 673 | 0.030 |
Why?
| | International Cooperation | 1 | 2017 | 52 | 0.030 |
Why?
| | Cells, Cultured | 1 | 2020 | 1586 | 0.030 |
Why?
| | Stellate Ganglion | 1 | 2016 | 3 | 0.030 |
Why?
| | Genome, Viral | 1 | 2017 | 83 | 0.030 |
Why?
| | Disability Evaluation | 1 | 2017 | 92 | 0.030 |
Why?
| | Rats | 2 | 2015 | 3180 | 0.030 |
Why?
| | Electrodes | 1 | 2016 | 35 | 0.030 |
Why?
| | Cross Infection | 1 | 2017 | 93 | 0.030 |
Why?
| | Respiratory Tract Infections | 1 | 2017 | 82 | 0.030 |
Why?
| | Mice, Obese | 1 | 2015 | 22 | 0.030 |
Why?
| | Reference Values | 1 | 2016 | 313 | 0.030 |
Why?
| | Genes, Reporter | 1 | 2015 | 88 | 0.030 |
Why?
| | Disease Models, Animal | 1 | 2020 | 1480 | 0.030 |
Why?
| | Biological Availability | 1 | 2015 | 108 | 0.030 |
Why?
| | Rats, Wistar | 1 | 2015 | 190 | 0.030 |
Why?
| | Young Adult | 1 | 2024 | 4326 | 0.030 |
Why?
| | Administration, Oral | 1 | 2015 | 455 | 0.030 |
Why?
| | Diet, High-Fat | 1 | 2015 | 237 | 0.030 |
Why?
| | Case-Control Studies | 1 | 2016 | 1198 | 0.030 |
Why?
| | Blood Glucose | 1 | 2015 | 473 | 0.030 |
Why?
| | Stroboscopy | 1 | 2012 | 4 | 0.020 |
Why?
| | Cohort Studies | 1 | 2017 | 1550 | 0.020 |
Why?
| | Observer Variation | 1 | 2012 | 132 | 0.020 |
Why?
| | Otolaryngology | 1 | 2012 | 61 | 0.020 |
Why?
| | H-Reflex | 1 | 2011 | 27 | 0.020 |
Why?
| | Cell Line, Tumor | 1 | 2015 | 1423 | 0.020 |
Why?
| | Electric Stimulation | 1 | 2011 | 107 | 0.020 |
Why?
| | Gene Expression Regulation | 1 | 2015 | 1004 | 0.020 |
Why?
| | Mice, Inbred C57BL | 1 | 2015 | 1897 | 0.020 |
Why?
| | Laryngeal Muscles | 1 | 2009 | 2 | 0.020 |
Why?
| | Vocal Cords | 1 | 2009 | 9 | 0.020 |
Why?
| | Nerve Regeneration | 1 | 2009 | 20 | 0.020 |
Why?
| | Laryngoscopy | 1 | 2009 | 59 | 0.020 |
Why?
| | Aged, 80 and over | 1 | 2017 | 3413 | 0.020 |
Why?
| | Poliomyelitis | 1 | 2008 | 5 | 0.020 |
Why?
| | Tachycardia | 1 | 2008 | 28 | 0.020 |
Why?
| | Spinal Cord | 1 | 2008 | 131 | 0.020 |
Why?
| | Cause of Death | 1 | 2008 | 162 | 0.020 |
Why?
| | Retrospective Studies | 1 | 2017 | 6643 | 0.010 |
Why?
| | Evidence-Based Medicine | 1 | 2006 | 269 | 0.010 |
Why?
| | Dimerization | 1 | 2003 | 51 | 0.010 |
Why?
| | Alanine | 1 | 2003 | 43 | 0.010 |
Why?
| | Electrophoresis, Polyacrylamide Gel | 1 | 2003 | 95 | 0.010 |
Why?
| | Serine | 1 | 2003 | 35 | 0.010 |
Why?
| | Prognosis | 1 | 2008 | 2113 | 0.010 |
Why?
| | Blotting, Western | 1 | 2003 | 592 | 0.010 |
Why?
| | Polymorphism, Restriction Fragment Length | 1 | 2002 | 66 | 0.010 |
Why?
| | Pedigree | 1 | 2002 | 125 | 0.010 |
Why?
| | Haplotypes | 1 | 2002 | 95 | 0.010 |
Why?
| | Magnetic Resonance Imaging | 1 | 2008 | 1536 | 0.010 |
Why?
| | Base Sequence | 1 | 2002 | 634 | 0.010 |
Why?
| | Amino Acid Sequence | 1 | 2002 | 571 | 0.010 |
Why?
| | Myocardium | 1 | 2003 | 478 | 0.010 |
Why?
| | Risk Factors | 1 | 2008 | 3945 | 0.010 |
Why?
| | DNA | 1 | 2002 | 548 | 0.010 |
Why?
| | Time Factors | 1 | 2002 | 2989 | 0.010 |
Why?
|
|
Kincaid's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|